Leave a clear path for the dialysis lifeline.

IN.PACT™ AV DCB:

  • Demonstrates 56% fewer reinterventions than PTA1
  • Slows the progression of restenosis
  • Minimizes the potential post-treatment limitations of stents
  • Offers superior performance compared to PTA through 36 months2

AV maintenance trial review

Only device to achieve > 80% primary patency† through six months in an AVF trial

IN.PACT™ AV DCB treats the cause of restenosis — not just the symptoms — helping to move your patients in the right direction. 

AV access maintenance trials — target lesion primary patency‡

See six-month outcomes from separate AV access maintenance trials evaluating PTA balloons, stents, and DCBs.†

† Target lesion primary patency in an AV fistula IDE randomized controlled trial.

‡ Primary patency rates are defined differently. Results are from different studies and may vary in a head-to-head comparison; charts are for illustration purposes only.

36-month data 

First and only DCB with superior, sustained results at 36 months2,10

Compared to PTA, the IN.PACT AV drug-coated balloon is the first and only DCB to show both superior and sustained results at 36 months in treating AV fistula lesions.

The highest reported primary patency of any DCB at 36 months.

Results from separate trials comparing drug-coated balloons to standard PTA for AV fistula maintenance.

Target lesion primary patency at 36 months‡ 
IN.PACT™ AV DCB§,2

Access circuit primary patency at 36 months‡ 
IN.PACT™ AV DCB¶,2

Target lesion primary patency at 24 months‡ 
Lutonix™ DCB◊,10

Access circuit primary patency at 24 months‡ 
Lutonix™ DCB#,10,11

Educational Programs

Related links